九洲药业：公司CDMO业务覆盖全球主要医药市场

Core Viewpoint - Jiuzhou Pharmaceutical (603456) has a significant presence in the global CDMO market, with approximately 80% of its business derived from overseas markets, primarily in Europe and the Asia-Pacific region [1]. Group 1 - The company’s CDMO business model involves collaboration with clients through single or annual procurement contracts [1]. - The specific details of the business model and regional operations can be found in the company's periodic reports disclosed on the Shanghai Stock Exchange [1].